journal article·2024-07-10

In Situ Aggregated Nanomanganese Enhances Radiation-Induced Antitumor Immunity

Jialong Xu, Chao Wang, Li Zhang, Chuan Zhao, Xiaozhi Zhao, Jinhui Wu

ACS Applied Materials & Interfaces· Volume 16· Issue 27
Publisher page

Abstract

Radiosensitizers play a pivotal role in enhancing radiotherapy (RT). One of the challenges in RT is the limited accumulation of nanoradiosensitizers and the difficulty in activating antitumor immunity. Herein, a smart strategy was used to achieve in situ aggregation of nanomanganese adjuvants (MnAuNP-C&B) to enhance RT-induced antitumor immunity. The aggregated MnAuNP-C&B system overcomes the shortcomings of small-sized nanoparticles that easily flow back into blood vessels and diffuse into surrounding tissues, and it also prolongs the retention time of nanomanganese within cancer cells and tumors. The MnAuNP-C&B system significantly enhances the radiosensitization effect in RT. Additionally, the pH-responsive disassembly of MnAuNP-C&B triggers the release of Mn 2+, further promoting RT-induced activation of the STING pathway and eliciting robust antitumor immunity. Overall, our study presents a smart strategy wherein in situ aggregation of nanomanganese effectively inhibits tumor growth through radiosensitization and the activation of antitumor immunity.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · interferon and immune responses · Extracellular vesicles in disease

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Medical School of Nanjing University, Nanjing 210093, China

Jiangsu Agri-Animal Husbandry Vocational College, Taizhou 225300, China

Department of Andrology, Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School, Nanjing University, Nanjing 210023, China

Chemistry and Biomedicine Innovation Centre, Nanjing University, Nanjing 210023, China

State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University, Nanjing 210023, China

Funding

National Key Research and Development Program of China · National Natural Science Foundation of China · Nanjing Special Fund for Life and Health Science and Technology

References (61)

Show source-provided references
1. 10.1038/s41571-023-00750-510.1038/s41571-023-00750-5 ↗
2. 10.1038/s41571-022-00709-y10.1038/s41571-022-00709-y ↗
3. 10.1038/s41551-023-01024-210.1038/s41551-023-01024-2 ↗
4. 10.1186/s12943-023-01801-210.1186/s12943-023-01801-2 ↗
5. 10.1186/s12943-023-01839-210.1186/s12943-023-01839-2 ↗
6. 10.1038/s41565-023-01373-810.1038/s41565-023-01373-8 ↗
7. 10.1039/D3MH00265A10.1039/D3MH00265A ↗
8. 10.1186/s12943-023-01798-810.1186/s12943-023-01798-8 ↗
9. 10.1016/j.jconrel.2023.01.00910.1016/j.jconrel.2023.01.009 ↗
10. 10.1002/adfm.20230336610.1002/adfm.202303366 ↗
11. 10.1038/s41392-023-01536-y10.1038/s41392-023-01536-y ↗
12. 10.1038/natrevmats.2016.1410.1038/natrevmats.2016.14 ↗
13. 10.1038/natrevmats.2017.2410.1038/natrevmats.2017.24 ↗
14. 10.1038/s41563-023-01630-010.1038/s41563-023-01630-0 ↗
15. 10.1038/nnano.2012.4510.1038/nnano.2012.45 ↗
16. 10.1038/nrclinonc.2010.13910.1038/nrclinonc.2010.139 ↗
17. 10.1016/j.semcancer.2019.11.00210.1016/j.semcancer.2019.11.002 ↗
18. 10.1021/acsnano.6b0232610.1021/acsnano.6b02326 ↗
19. 10.1002/advs.20180180610.1002/advs.201801806 ↗
20. 10.1021/nl900031y10.1021/nl900031y ↗
21. 10.1016/j.nantod.2023.10200410.1016/j.nantod.2023.102004 ↗
22. 10.1021/acsnano.5b0747310.1021/acsnano.5b07473 ↗
23. 10.1002/advs.20210434910.1002/advs.202104349 ↗
24. 10.1021/acs.jpca.2c0048910.1021/acs.jpca.2c00489 ↗
25. 10.1002/wnan.188610.1002/wnan.1886 ↗
26. 10.1016/j.immuni.2014.10.01910.1016/j.immuni.2014.10.019 ↗
27. 10.1038/ni92110.1038/ni921 ↗
28. 10.1038/s41573-018-0011-210.1038/s41573-018-0011-2 ↗
29. 10.1016/j.immuni.2018.09.01610.1016/j.immuni.2018.09.016 ↗
30. 10.1016/j.immuni.2017.07.01610.1016/j.immuni.2017.07.016 ↗
31. 10.1038/s41586-018-0705-y10.1038/s41586-018-0705-y ↗
32. 10.1126/science.abb425510.1126/science.abb4255 ↗
33. 10.1126/science.aba609810.1126/science.aba6098 ↗
34. 10.1038/ncomms1561810.1038/ncomms15618 ↗
35. 10.1038/s41577-018-0117-010.1038/s41577-018-0117-0 ↗
36. 10.1016/j.jconrel.2021.01.03610.1016/j.jconrel.2021.01.036 ↗
37. 10.1016/j.immuni.2018.03.01710.1016/j.immuni.2018.03.017 ↗
38. 10.1038/s41467-022-33301-010.1038/s41467-022-33301-0 ↗
39. 10.1016/j.colsurfb.2011.06.00910.1016/j.colsurfb.2011.06.009 ↗
40. 10.1038/nchem.48010.1038/nchem.480 ↗
41. 10.1038/s41563-019-0503-410.1038/s41563-019-0503-4 ↗
42. 10.1021/jacs.2c1318910.1021/jacs.2c13189 ↗
43. 10.1021/acsnano.2c0618610.1021/acsnano.2c06186 ↗
44. 10.1002/smll.20180234210.1002/smll.201802342 ↗
45. 10.1002/anie.20131113610.1002/anie.201311136 ↗
46. 10.1002/adma.20210578310.1002/adma.202105783 ↗
47. 10.1016/j.nantod.2022.10140510.1016/j.nantod.2022.101405 ↗
48. 10.1039/c2nr31227a10.1039/c2nr31227a ↗
49. 10.1016/j.nano.2020.10224110.1016/j.nano.2020.102241 ↗
50. 10.1038/physci241020a010.1038/physci241020a0 ↗
51. 10.1158/2159-8290.CD-19-076110.1158/2159-8290.CD-19-0761 ↗
52. 10.1126/sciadv.aat171910.1126/sciadv.aat1719 ↗
53. 10.1016/j.immuni.2018.03.01710.1016/j.immuni.2018.03.017 ↗
54. 10.1002/adma.20220540910.1002/adma.202205409 ↗
55. 10.1016/j.ccell.2018.03.02710.1016/j.ccell.2018.03.027 ↗
56. 10.1016/j.colsurfb.2011.06.00910.1016/j.colsurfb.2011.06.009 ↗
57. 10.1038/s41422-020-00395-410.1038/s41422-020-00395-4 ↗
58. 10.1038/s41565-018-0342-510.1038/s41565-018-0342-5 ↗
59. 10.1002/advs.20210007410.1002/advs.202100074 ↗
60. 10.1021/acsnano.6b0507010.1021/acsnano.6b05070 ↗
61. 10.1039/D2RA04004B10.1039/D2RA04004B ↗